We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Generic drug prescription rates could increase by another 15 percent under the new Medicare Rx drug law, which contains government regulations and private market incentives to use generics, according to federal officials and private-sector healthcare executives.
The Generic Pharmaceutical Association (GPhA) has come out against the practice of generic firms cutting deals with brand firms to market so-called “authorized generics” — a practice the trade group contends devalues the 180-day exclusivity provision in the federal drug patent law.
Despite what critics charge, drug manufacturers say they won't reap billions of dollars in additional profits under the new Medicare prescription drug law and contend the benefit will have little overall effect on revenues or research and development efforts.
Minnesota Gov. Tim Pawlenty wants the board that oversees investment of state pension funds to use its standing as a Pfizer shareholder to pressure the company to change its drug prices.
In what could become a trend among states trying to lower drug prices, South Dakota lawmakers this week passed legislation requiring pharmaceutical benefits managers (PBMs) to reveal the rebates and payments they receive from pharmaceutical firms.
In an effort to quell the rising call for reimportation, as well the increasingly loud whispers on Capitol Hill about price controls, the chairman and chief executive officer of Schering-Plough yesterday announced a three-part proposal to help uninsured Americans that includes access to free prescription drugs.
The federal government has not yet given a green light to a multistate prescription drug buying program that lets states combine their Medicaid purchasing power to leverage additional discounts from drugmakers.
Small and developmental drug companies take after their big pharma cousins in at least one respect: Despite the decreasing amount of face-to-face time that sales representatives have with physicians, drugmakers large and small — even those that don’t have a product on the market yet — are spending more on their sales efforts.